美国支持豁免对新冠疫苗知识产权保护 开拓/国药/康希诺/复星医药急挫11%-22%
美国总统拜登表示,将支持世界贸易组织的一项提议,即豁免对新冠疫苗知识产权保护,以帮助加快全球生产。市场预计消息不利疫苗股。
於本港上市疫苗股以复星医药(02196.HK)表现最差,股价由纪录高位掉头三连吐,尤其是今早股价失守10天线(47.8元)後,沽盘持续涌现,最低见41.7元喘定,现造43.6元,急挫逾22%,但20天线(42.1元)失而复得,成交急增至4,375万股,为近几年罕见。
康希诺生物-B(06185.HK)四连跌,尤其是今早股价一举跌破50天、20天及50天线(318.9-359.2元),现造286元即市低位,急挫近22%,成交增至365万股。
国药(01099.HK)也跌破10天及20天线(24.4元及23.3元),最低见21.85元,现造22.5元,挫近13%,成交增至2,391万股。开拓药业-B(09939.HK)由收市纪录高位三连跌,今天股价失守10天线(66.65元),最低见58.1元,现造62.3元,续挫11%,成交增至319万股
蓝筹中生制药(01177.HK)一举失守5条移动平均线(7.8-8.4元),报7.76元,续跌7.6%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.